Key Drivers
- Strong Margins
- Weak Liquidity
- High Leverage
AIAI Summary
HLN is now better viewed as a self-help turnaround than a pure defensive name, with strong cash generation and buybacks supporting the case, but the stock likely stays capped until U.S. sales normalization and brand-led growth show up in reported results, especially given leverage and a valuation that already prices in some recovery.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Weak Liquidity
- •High Leverage
HLN is a profitable, cash-generative business with strong interest coverage and solid margins, but its leveraged balance sheet, weak liquidity, and intangible-heavy asset base temper the valuation appeal.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Selloff slowing
- •Base forming
HLN has remained in a last month downtrend with lower highs, but the selloff is slowing near $8.90-$9.10, so holding $8.91-$8.96 could set up a bounce while a break below it would confirm continued weakness.
Price has clustered near $8.90-$9.10, hinting at a short-term base after a steady decline
Sentiment & News
Key News Insights:
- •Q1 Mix
- •U.S. Marketing
- •Product Launches
Haleon's Q1 update showed modest growth constrained by a weak cold and flu season but supported by strong toothpaste sales, while new U.S. marketing leadership, product innovation, and analyst/investor support point to steady brand momentum.
The news is mildly positive for Haleon, suggesting resilient core demand and continued brand-building, though category softness may cap near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings